Omnihealth Practice

DIABETES & ENDOCRINOLOGY

More than glycated hemoglobin: Dapagliflozin preserves cardiorenal functions in patients with type 2 diabetes mellitus

21 Sep 2021

Breaking the vicious cycle of cardiac, renal and metabolic risks in patients at risk of chronic kidney disease

13 Jul 2021

What not to ignore when diabetes interacts with acute and chronic kidney diseases: A local case sharing

30 Dec 2020

Managing the early-onset type 2 diabetes mellitus: Target the major hurdles

29 Jun 2020

Managing the early-onset type 2 diabetes mellitus: Target the major hurdles

People with young-onset diabetes have a worse metabolic risk profile compared to those with late-onset disease. This group has higher risks for cardiovascular and kidney complications at any given age, driven by the longer disease duration.1 In Hong Kong, while the mortality rate decrease in people

29 Jun 2020

Dr. Luk, On-Yan Andrea

Associate Professor,
Department of Medicine & Therapeutics,
The Chinese University of Hong Kong

ENDO 2020

30 - 31 March 2020 |

San Francisco, United States

More than glycated hemoglobin: Dapagliflozin preserves cardiorenal functions in patients with type 2 diabetes mellitus

CARDIOLOGY DIABETES & ENDOCRINOLOGY

21 Sep 2021

Professor Jonathan Shaw

Deputy Director,
Clinical and Population Health,
Baker Heart and Diabetes Institute,
Melbourne, Australia

What not to ignore when diabetes interacts with acute and chronic kidney diseases: A local case sharing

While they may not necessarily have a causal relationship, both chronic kidney disease (CKD) and diabetes mellitus (DM) have become increasingly more prevalent worldwide.1 As these conditions could be risk factors for developing acute kidney injury (AKI),2 CKD and DM must be carefully managed to pre

30 Dec 2020

Dr. Cheung, Siu-Fai

Specialist in Nephrology

Dasiglucagon shown as a promising therapeutic for severe hypoglycemia in a recent phase 3 trial

Published recently in Diabetes Care, a phase 3 study demonstrated the rapid hypoglycemia reversing capability of dasiglucagon among adult patients with type 1 diabetes mellitus (T1DM) who were experiencing severe insulin-induced hypoglycemia.1 Together with the results from similar studies targeting

29 Jun 2021

Semaglutide aids weight loss in adults with type 2 diabetes and reduces major adverse cardiovascular events

Weight control remains an indispensable component for the clinical management of type 2 diabetes mellitus (T2DM) in preventing cardiometabolic morbidity.1-3 People with T2DM who received weekly subcutaneous injection of semaglutide 2.4mg achieved superior and clinically meaningful reduction of body

08 Apr 2021

DIABETES & ENDOCRINOLOGY

No response to exercise? The gut microbiota is to blame

29 Feb 2020